SK2242001A3 - Tpl-2/cot kinase and methods of use - Google Patents

Tpl-2/cot kinase and methods of use Download PDF

Info

Publication number
SK2242001A3
SK2242001A3 SK224-2001A SK2242001A SK2242001A3 SK 2242001 A3 SK2242001 A3 SK 2242001A3 SK 2242001 A SK2242001 A SK 2242001A SK 2242001 A3 SK2242001 A3 SK 2242001A3
Authority
SK
Slovakia
Prior art keywords
tpl
compound
compounds
activity
polypeptide
Prior art date
Application number
SK224-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Hamish John Allen
Richard Woodward Dixon
Joanne Sara Kamens
Dineli Wickramasinghe
Yajun Xu
Monica Polidoro Belich
Leland Herries Johnston
Steven Charles Ley
Andres Salmeron
Original Assignee
Basf Ag
Medical Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9817930.2A external-priority patent/GB9817930D0/en
Priority claimed from GBGB9827712.2A external-priority patent/GB9827712D0/en
Application filed by Basf Ag, Medical Res Council filed Critical Basf Ag
Publication of SK2242001A3 publication Critical patent/SK2242001A3/sk

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
SK224-2001A 1998-08-18 1999-08-13 Tpl-2/cot kinase and methods of use SK2242001A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9817930.2A GB9817930D0 (en) 1998-08-18 1998-08-18 Pathway
GBGB9827712.2A GB9827712D0 (en) 1998-12-16 1998-12-16 Pathway
PCT/US1999/018543 WO2000011191A2 (en) 1998-08-18 1999-08-13 Tpl-2/cot kinase and methods of use

Publications (1)

Publication Number Publication Date
SK2242001A3 true SK2242001A3 (en) 2001-10-08

Family

ID=26314223

Family Applications (1)

Application Number Title Priority Date Filing Date
SK224-2001A SK2242001A3 (en) 1998-08-18 1999-08-13 Tpl-2/cot kinase and methods of use

Country Status (22)

Country Link
US (1) US20020099169A1 (ja)
EP (1) EP1105501A2 (ja)
JP (1) JP4719831B2 (ja)
KR (1) KR20010085407A (ja)
CN (1) CN1323346A (ja)
AU (1) AU767973B2 (ja)
BG (1) BG105345A (ja)
BR (1) BR9913070A (ja)
CA (1) CA2339036A1 (ja)
CZ (1) CZ2001625A3 (ja)
HK (1) HK1041901A1 (ja)
HU (1) HUP0103797A2 (ja)
ID (1) ID28955A (ja)
IL (1) IL141355A0 (ja)
MX (1) MXPA01001747A (ja)
NO (1) NO20010786L (ja)
NZ (1) NZ510313A (ja)
PL (1) PL347137A1 (ja)
RU (1) RU2001107122A (ja)
SK (1) SK2242001A3 (ja)
TR (2) TR200103840T2 (ja)
WO (1) WO2000011191A2 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660906B1 (en) 2000-03-08 2003-12-09 Thomas Jefferson University Tpl2 transgenic knockout mice
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
GB0402661D0 (en) * 2004-02-06 2004-03-10 Medical Res Council TPL2 and its expression

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514505A (en) * 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
UA71889C2 (uk) * 1996-04-02 2005-01-17 Йєда Рісерч Енд Дівелопмент Ко. Лтд. Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування

Also Published As

Publication number Publication date
RU2001107122A (ru) 2003-04-20
WO2000011191A2 (en) 2000-03-02
BG105345A (en) 2001-12-31
AU767973B2 (en) 2003-11-27
ID28955A (id) 2001-07-19
MXPA01001747A (es) 2003-06-06
NO20010786L (no) 2001-04-17
JP2002531058A (ja) 2002-09-24
BR9913070A (pt) 2001-05-08
CN1323346A (zh) 2001-11-21
HK1041901A1 (zh) 2002-07-26
PL347137A1 (en) 2002-03-25
IL141355A0 (en) 2002-03-10
CZ2001625A3 (cs) 2002-02-13
JP4719831B2 (ja) 2011-07-06
KR20010085407A (ko) 2001-09-07
HUP0103797A2 (hu) 2003-10-28
AU5563399A (en) 2000-03-14
NO20010786D0 (no) 2001-02-16
EP1105501A2 (en) 2001-06-13
TR200100624T2 (tr) 2001-08-21
TR200103840T2 (tr) 2002-06-21
NZ510313A (en) 2003-11-28
CA2339036A1 (en) 2000-03-02
WO2000011191A3 (en) 2000-06-08
US20020099169A1 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
JP6025758B2 (ja) Ｎｆａｔの制御因子
US6630297B2 (en) Methods of screening for agents that modulate the interaction of human ECT2 polypeptide with an ECT2 binding target
US20070087988A1 (en) Hematopoietic progenitor kinase 1 for modulation of an immune response
US20040053841A1 (en) Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US6596473B1 (en) Active survival domains of IGF-IR and methods of use
US20040101879A1 (en) Srebp pathway modulation through targeting hisrs
JP2004524021A (ja) ＨｉｓＲＳをターゲッティングすることによるＳＲＥＢＰ経路の調節
US6528270B1 (en) Methods for identifying compounds for treatment of cell proliferative disorders associated with adaptor protein interactions
US7049395B2 (en) Anti-inflammatory compounds and uses thereof
AU767973B2 (en) TPL-2/COT kinase and methods of use
US8809500B2 (en) Complexes comprising mammalian raptor polypeptide and mammalian mTOR polypeptide
US20030219427A1 (en) TPL-2/COT kinase and methods of use
US20080199469A1 (en) Regulation and function of TPL-2
ZA200102200B (en) TPL-2/cot kinase and methods of use.
EP1294872B1 (en) Human trp-like calcium channel protein-2 (tlcc-2)
US20080026992A1 (en) Tyrosine Phosphorylation of Cdk Inhibitor Proteins of the Cip/Kip Family
JP4299990B2 (ja) 新規なｓｍｇ−１
JP2002530349A (ja) Ｎｆ−ａｔ媒介の心臓肥大、それに関係する方法及び試薬
WO2003083117A2 (en) Vascularization controlling gene
JP2000135100A (ja) 抗ウイルス剤を同定するためのアッセイ法
CHENGCHEN Study of the Associated Proteins of STAT3 and Characterization of their Functions: Roles of GRIM-19 and PIN1 in the Regulation of STAT3 Activity
WO2004019994A1 (ja) Ａｒｋ５

Legal Events

Date Code Title Description
FB9A Suspension of patent application procedure